- Home
- ITOS
as 11-07-2024 3:34pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 323.2M | IPO Year: | 2020 |
| Target Price: | $32.50 | AVG Volume (30 days): | 692.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.41 - $18.75 | Next Earning Date: | 11-15-2024 |
| Revenue: | $35,000,000 | Revenue Growth: | -59.30% |
| Revenue Growth (this year): | 271.18% | Revenue Growth (next year): | -85.39% |
Latest iTeos Therapeutics Inc. News
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
GuruFocus.com
23 days ago
BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc
GuruFocus.com
a month ago
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc
Investor's Business Daily
2 months ago
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
MT Newswires
2 months ago
Wedbush Raises Price Target on iTeos Therapeutics to $25 From $21, Keeps Outperform Rating
Pharmaceutical Technology
2 months ago
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
BioPharma Dive
2 months ago
TIGIT drug from iTeos shrinks lung tumors in trial
GlobeNewswire
2 months ago
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
Compare ITOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITOS iTeos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.